The impact of abdominal pain on global measures in patients with chronic idiopathic constipation, before and after treatment with linaclotide: a pooled analysis of two randomised, double-blind, placebo-controlled, phase 3 trials

L Chang, A J Lembo, B J Lavins, S J Shiff, X Hao, J G Chickering, X D Jia, M G Currie, C B Kurtz, J M Johnston, L Chang, A J Lembo, B J Lavins, S J Shiff, X Hao, J G Chickering, X D Jia, M G Currie, C B Kurtz, J M Johnston

Abstract

Background: Few clinical trials in chronic idiopathic constipation (CIC) patients have evaluated abdominal symptom severity and whether CIC patients with abdominal symptoms respond similarly to patients with limited abdominal symptoms.

Aims: To examine abdominal symptom severity and relationships between symptoms and global measures at baseline; compare linaclotide's effect on symptoms in subpopulations with more or less abdominal pain; and assess relationships between symptom improvement and global measures in these two subpopulations.

Methods: In two phase 3 trials, patients meeting modified Rome II CIC criteria were assigned to linaclotide 145 μg, 290 μg, or placebo once daily. Patients rated abdominal and bowel symptoms daily during 2-week pre-treatment and 12-week treatment periods. Linaclotide's effect on symptoms and global measures [constipation severity, health-related quality of life (HRQOL), treatment satisfaction] and their inter-relationships were assessed in post hoc analyses of abdominal pain subpopulations.

Results: Of 1271 CIC patients, 23%, 32%, and 43% reported moderate-to-severe abdominal pain, discomfort, and bloating, respectively, during baseline. In more-severe abdominal pain patients, abdominal symptoms were more strongly correlated than bowel symptoms with global measures, but in less-severe abdominal pain patients, abdominal and bowel symptoms were similarly correlated with global measures, at baseline and post-treatment. Linaclotide significantly improved all symptoms and global measures in both subpopulations.

Conclusions: When abdominal pain is present in CIC, abdominal and not bowel symptoms may drive patient assessments of constipation severity, HRQOL, and treatment satisfaction. Linaclotide (145 μg and 290 μg) is an effective treatment for both abdominal and bowel symptoms, even in CIC patients with more severe abdominal pain at baseline. (Clinicaltrials.gov: NCT00765882, NCT00730015).

© 2014 The Authors. Alimentary Pharmacology & Therapeutics published by John Wiley & Sons Ltd.

Figures

Figure 1
Figure 1
Subpopulations of patients with moderate-to-severe abdominal symptoms (ITT population). Venn diagram depicting the relative sizes and overlaps of the subpopulations of patients with moderate-to-severe (≥3) abdominal pain, abdominal discomfort, and abdominal bloating at baseline in the ITT population.
Figure 2
Figure 2
Correlations of baseline global measures with baseline abdominal and bowel symptoms. (a) Correlations of constipation severity score at baseline with abdominal and bowel symptoms at baseline. Pearson correlation coefficients, r, absolute values shown; *P < 0.05. (b) Correlations of PAC-QOL overall score at baseline with abdominal and bowel symptoms at baseline. Pearson correlation coefficients, r, absolute values shown; *P < .05.
Figure 3
Figure 3
Weekly mean change from baseline in abdominal pain. (a) Mean change from baseline in abdominal pain (LOCF) by week during the 12-week treatment period, by dose group in patients who had none-to-mild abdominal pain at baseline. Abdominal pain measured on a 5-point ordinal scale (1 = none to 5 = very severe). (b) Mean change from baseline in abdominal pain (LOCF) by week during the 12-week treatment period, by dose group in patients who had moderate-to-severe abdominal pain at baseline. Abdominal pain measured on a 5-point ordinal scale (1 = none to 5 = very severe).
Figure 4
Figure 4
Correlation of global measures after treatment with improvement in abdominal and bowel symptoms. (a) Correlation of constipation severity (week 12 LOCF) with improvement in abdominal and bowel symptoms (baseline to week 12 LOCF). Pearson correlation coefficients, r, absolute values shown; *P < 0.05. (b) Correlation of PAC-QOL overall score (week 12) with improvement in abdominal and bowel symptoms (baseline to week 12 LOCF). Pearson correlation coefficients, r, absolute values shown; *P < 0.05. (c) Correlation of treatment satisfaction (week 12 LOCF) with improvement in abdominal and bowel symptoms (baseline to week 12 LOCF). Pearsoncorrelation coefficients, r, absolute values shown; *P < 0.05.

References

    1. Higgins PD, Johanson JF. Epidemiology of constipation in North America: a systematic review. Am J Gastroenterol. 2004;99:750–9.
    1. Suares NC, Ford AC. Diagnosis and treatment of irritable bowel syndrome. Discov Med. 2011;11:425–33.
    1. Peppas G, Alexiou VG, Mourtzoukou E, Falagas ME. Epidemiology of constipation in Europe and Oceania: a systematic review. BMC Gastroenterol. 2008;8:5.
    1. Lembo A, Camilleri M. Chronic constipation. N Engl J Med. 2003;349:1360–8.
    1. Wald A, Scarpignato C, Kamm MA, et al. The burden of constipation on quality of life: results of a multinational survey. Aliment Pharmacol Ther. 2007;26:227–36.
    1. Sun SX, Dibonaventura M, Purayidathil FW, Wagner JS, Dabbous O, Mody R. Impact of chronic constipation on health-related quality of life, work productivity, and healthcare resource use: an analysis of the National Health and Wellness Survey. Dig Dis Sci. 2011;56:2688–95.
    1. Irvine EJ, Ferrazzi S, Pare P, Thompson WG, Rance L. Health-related quality of life in functional GI disorders: focus on constipation and resource utilization. Am J Gastroenterol. 2002;97:1986–93.
    1. Belsey J, Greenfield S, Candy D, Geraint M. Systematic review: impact of constipation on quality of life in adults and children. Aliment Pharmacol Ther. 2010;31:938–49.
    1. Everhart JE, Ruhl CE. Burden of digestive diseases in the United States part II: lower gastrointestinal diseases. Gastroenterology. 2009;136:741–54.
    1. Cai Q, Buono JL, Spalding WM, et al. Healthcare costs among patients with chronic constipation: a retrospective claims analysis in a commercially insured population. J Med Econ. 2013;17:148–58.
    1. Sethi S, Mikami S, Leclair J, et al. Inpatient burden of constipation in the United States: an analysis of national trends in the United States from 1997 to 2010. Am J Gastroenterol. 2014;109:250–6.
    1. Nyrop KA, Palsson OS, Levy RL, et al. Costs of health care for irritable bowel syndrome, chronic constipation, functional diarrhoea and functional abdominal pain. Aliment Pharmacol Ther. 2007;26:237–48.
    1. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology. 2006;130:1480–91.
    1. Bharucha AE, Pemberton JH, Locke GR. American Gastroenterological Association technical review on constipation. Gastroenterology. 2013;144:218–38.
    1. Bharucha AE, Locke GR, Zinsmeister AR, et al. Differences between painless and painful constipation among community women. Am J Gastroenterol. 2006;101:604–12.
    1. Drossman DA, Morris C, Hu Y, et al. Further characterization of painful constipation (PC): clinical features over one year and comparison with IBS. J Clin Gastroenterol. 2008;42:1080–8.
    1. Mearin F, Lacy BE. Diagnostic criteria in IBS: useful or not? Neurogastroenterol Motil. 2012;24:791–801.
    1. Johanson JF, Kralstein J. Chronic constipation: a survey of the patient perspective. Aliment Pharmacol Ther. 2007;25:599–608.
    1. Bharucha AE, Dorn SD, Lembo A, Pressman A. American gastroenterological association medical position statement on constipation. Gastroenterology. 2013;144:211–7.
    1. Pare P. The approach to diagnosis and treatment of chronic constipation: suggestions for a general practitioner. Can J Gastroenterol. 2011;25:36–40.
    1. Thompson WG, Longstreth GF, Drossman DA, Heaton KW, Irvine EJ, Muller-Lissner SA. Functional bowel disorders and functional abdominal pain. Gut. 1999;45(Suppl. 2):II43–7.
    1. Frissora CL. Diagnosis, treatment, and management of irritable bowel syndrome with constipation and chronic constipation. Med Gen Med. 2005;7:71.
    1. Bassotti G, Carlani E, Baldón M, Gullà N, Morozzi B, Villanacci V. Painful constipation: a neglected entity? Rev Esp Enferm Dig. 2011;103:25–8.
    1. Shekhar C, Monaghan PJ, Morris J, et al. Rome III functional constipation and irritable bowel syndrome with constipation are similar disorders within a spectrum of sensitization, regulated by serotonin. Gastroenterology. 2013;145:749–57. quiz e13-4.
    1. Ford AC, Bercik P, Morgan DG, Bolino C, Pintos-Sanchez MI, Moayyedi P. Characteristics of functional bowel disorder patients: a cross-sectional survey using the Rome III criteria. Aliment Pharmacol Ther. 2014;39:312–21.
    1. Rey E, Balboa A, Mearin F. Chronic constipation, irritable bowel syndrome with constipation and constipation with pain/discomfort: similarities and differences. Am J Gastroenterol. 2014;109:876–84.
    1. Wong RK, Palsson OS, Turner MJ, et al. Inability of the Rome III criteria to distinguish functional constipation from constipation-subtype irritable bowel syndrome. Am J Gastroenterol. 2010;105:2228–34.
    1. Brandt LJ, Prather CM, Quigley EM, Schiller LR, Schoenfeld P, Talley NJ. Systematic review on the management of chronic constipation in North America. Am J Gastroenterol. 2005;100(Suppl. 1):S5–21.
    1. Talley NJ. Differentiating functional constipation from constipation-predominant irritable bowel syndrome: management implications. Rev Gastroenterol Disord. 2005;5:1–9.
    1. Frissora CL, Koch KL. Symptom overlap and comorbidity of irritable bowel syndrome with other conditions. Curr Gastroenterol Rep. 2005;7:264–71.
    1. Lacy BE, Weiser K, De LR. The treatment of irritable bowel syndrome. Therap Adv Gastroenterol. 2009;2:221–38.
    1. Spiegel B, Strickland A, Naliboff BD, Mayer EA, Chang L. Predictors of patient-assessed illness severity in irritable bowel syndrome. Am J Gastroenterol. 2008;103:2536–43.
    1. Lembo AJ, Schneier HA, Shiff SJ, et al. Two randomized trials of linaclotide for chronic constipation. N Engl J Med. 2011;365:527–36.
    1. Rao S, Lembo AJ, Shiff SJ, et al. A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation. Am J Gastroenterol. 2012;107:1714–25.
    1. Chey WD, Lembo AJ, Lavins BJ, et al. Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety. Am J Gastroenterol. 2012;107:1702–12.
    1. Drossman DA, Corazziari E, Talley NJ, Thompson WG, Whitehead WE. Functional bowel disorders and functional abdominal pain. In: Drossman DA, editor. ROME II: The Functional Gastrointestinal Disorders. Degnon Associates: McLean, Virginia, USA; 2000. pp. 360–91.
    1. Lewis SJ, Heaton KW. Stool form scale as a useful guide to intestinal transit time. Scand J Gastroenterol. 1997;32:920–4.
    1. Marquis P, De La Loge C, Dubois D, McDermott A, Chassany O. Development and validation of the Patient Assessment of Constipation Quality of Life questionnaire. Scand J Gastroenterol. 2005;40:540–51.
    1. Palsson OS, Baggish JS, Turner MJ, Whitehead WE. IBS patients show frequent fluctuations between loose/watery and hard/lumpy stools: implications for treatment. Am J Gastroenterol. 2012;107:286–95.
    1. Johnston JM, Kurtz CB, Macdougall JE, et al. Linaclotide improves abdominal pain and bowel habits in a phase IIb study of patients with irritable bowel syndrome. Gastroenterology. 2010;139:1877–86.
    1. Rao S. Phase 3 clinical trial of linaclotide in patients with IBS-C demonstrates significant improvements in abdominal pain and bowel symptoms. Neurogastroenterol Motil. 2011;23:2.
    1. Locke GR, Zinsmeister AR, Fett SL, Melton LJ, Talley NJ. Overlap of gastrointestinal symptom complexes in a US community. Neurogastroenterol Motil. 2005;17:29–34.
    1. Basilisco G, Coletta M. Chronic constipation: a critical review. Dig Liver Dis. 2013;45:886–93.
    1. Posserud I, Syrous A, Lindström L, Tack J, Abrahamsson H, Simrén M. Altered rectal perception in irritable bowel syndrome is associated with symptom severity. Gastroenterology. 2007;133:1113–23.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel